CXCL13 and melanoma: To find the distribution of this CXCL13+ CD8-Tterm.ex population and other T cell populations among individual patients, we grouped samples into rGBM, BrM arising from melanoma, and BrM arising from other cancer types, irrespective of immunotherapy treatment, and used the Kruskal-Wallis test to assess proportional differences (Supplemental Figure 2D).